Core Insights - DarioHealth Corp. has surpassed 100 scientific studies, establishing itself as a trusted partner for organizations aiming to reduce costs and improve health outcomes in digital health delivery [1][2][3] Group 1: Research and Validation - The milestone of 100 studies places Dario among the top digital health vendors in terms of the volume and depth of scientifically reviewed evidence, which is increasingly demanded by self-insured employers and health plans [2][3] - Dario's research includes a significant number of independent, third-party investigator-initiated studies, showcasing a mature evidence base in digital health [3][8] - The studies feature large populations, longitudinal designs, and independent validations, demonstrating actual claims reduction and measurable health improvements rather than modeled results [8] Group 2: Value Proposition - Dario's user-centric platform offers continuous and customized care, promoting sustainable behavior change and exceptional user satisfaction [5][6] - The company’s approach disrupts traditional episodic healthcare, empowering individuals to manage chronic conditions effectively [4][5] - As healthcare purchasers shift towards value-based decision-making, Dario's expanding portfolio of peer-reviewed publications reinforces its role as an outcomes-driven partner capable of delivering measurable impact [3][4]

Core Insights - DarioHealth Corp. has added 34 new employer clients in the past two weeks, bringing the total to 79 clients year-to-date, exceeding its 2025 target by 98% [1][2][3] - The new clients primarily selected DarioHealth to address cardiometabolic conditions, indicating a market shift towards integrated digital health platforms [2][3] - DarioHealth's platform has demonstrated significant clinical outcomes, including a 1.4% reduction in eHbA1c, a 38% reduction in blood pressure, and an average 10% reduction in Body Mass Index (BMI) among participants [3][4] Company Performance - The revenue from the newly signed clients is expected to begin in Q1 2026, reflecting strong market momentum and demand for DarioHealth's products [1][3] - DarioHealth's platform has shown a 23% lower hospitalization rate and 26% lower all-cause charges compared to traditional care, highlighting its effectiveness [4] Market Position - DarioHealth is positioned as a leader in the digital health market, focusing on chronic conditions management through a user-centric, multi-chronic condition platform [5][6] - The company emphasizes the importance of delivering measurable clinical and financial outcomes, which resonates with self-insured employers [3][4]

Core Viewpoint - DarioHealth Corp. will release its financial results for the second quarter of 2025 on August 12, 2025, and will host a conference call to discuss these results [1][2]. Company Overview - DarioHealth Corp. is a leader in the digital health market, focusing on chronic condition management through a user-centric digital therapeutics platform [4]. - The platform provides personalized interventions driven by data analytics and coaching for conditions such as diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health [4]. Conference Call Details - The conference call is scheduled for August 12, 2025, at 8:30 a.m. Eastern Time, with dial-in options for domestic and international participants [3]. - A replay of the call will be available approximately three hours after the event and can be accessed until August 26, 2025 [3]. User-Centric Approach - DarioHealth's platform offers continuous and customized care, aiming to disrupt traditional episodic healthcare approaches [5]. - This approach promotes sustainable behavior change and enhances user satisfaction and retention [5]. Global Reach - DarioHealth provides its solutions to health plans, self-insured employers, care providers, and consumers globally [6].

Core Insights - DarioHealth Corp. has presented new research demonstrating sustained outcomes for GLP-1 users and an 89% accuracy in AI-driven blood glucose predictions, indicating the company's strong position in the digital health market [1][2][6] Group 1: Research Findings - A significant reduction in eA1c levels from 9.0% to 6.7% was observed in GLP-1 users, with sustained results for six months post-medication discontinuation [2][8] - Users of Dario's platform maintained stable outcomes without significant weight or glucose rebound after stopping GLP-1 medication, addressing a critical challenge in chronic condition management [4][8] - The studies highlight the importance of integrated digital tools in enhancing medication adherence and optimizing health outcomes [5][6] Group 2: AI and Personalization - Dario's AI research achieved an 89% accuracy in predicting future blood glucose levels, utilizing user behavior and activity data [7][10] - The company's next-generation AI platform aims to provide personalized interventions based on real-time behaviors and clinical data, enhancing chronic condition management [6][9] - Age was identified as a significant factor influencing outcomes, with older adults showing stronger results through increased engagement in lifestyle activities [14] Group 3: Commercial Strategy - Dario is actively leveraging its research findings in discussions with payers and self-insured employers to offer integrated solutions for chronic condition management, particularly in GLP-1 optimization [3][10] - The company believes its platform can maximize return on investment for health plans and employers implementing GLP-1 programs, thereby enhancing commercial value [6][10]

Core Viewpoint - DarioHealth Corp. will release its financial results for the first quarter of 2025 on May 14, 2025, and will host a conference call to discuss these results [1][2]. Group 1: Conference Call Details - The conference call is scheduled for May 14, 2025, at 8:30 a.m. Eastern Time [3]. - Participants can join via a domestic dial-in number (1-800-717-1738) or an international number (1-646-307-1865) [3]. - A replay of the call will be available approximately two hours after the event until May 28, 2025 [3]. Group 2: Company Overview - DarioHealth Corp. is a leader in the digital health market, focusing on chronic condition management through a user-centric digital therapeutics platform [4]. - The platform provides personalized interventions for conditions such as diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health [4]. - DarioHealth's approach aims to empower users to make sustainable lifestyle changes, enhancing user satisfaction and retention [5]. Group 3: Market Reach - DarioHealth offers its solutions globally to health plans, self-insured employers, care providers, and consumers [6].

Company Leadership Transition - DarioHealth Corp. announced the retirement of Chief Financial Officer Zvi Ben-David, effective May 15, 2025 [1][2] - Chen Franco-Yehuda has been appointed as the new Chief Financial Officer, Treasurer, and Secretary, set to assume the role upon Mr. Ben-David's retirement [2][3] - Mr. Ben-David will assist the company in an advisory capacity until the end of June 2025 to ensure a smooth transition [2] New CFO's Background - Chen Franco-Yehuda brings extensive financial leadership experience, particularly in corporate finance, capital markets, and strategic growth initiatives [3] - She previously served as CFO at Pluri Inc., where she led financial strategy and secured substantial capital through various fundraising rounds [4] - Franco-Yehuda has a background as an Audit/Assurance Manager at PwC and is a licensed CPA in Israel [5] Company Growth and Strategy - Under Mr. Ben-David's leadership, DarioHealth transformed from a single-condition solution provider to a comprehensive multi-condition digital health platform [6] - The company has expanded its offerings across various health conditions, including diabetes, hypertension, mental health, weight management, and musculoskeletal care [6] - DarioHealth aims to leverage Franco-Yehuda's expertise to continue driving innovation and growth in the digital health sector [6][7]